Journal of Cardiovascular Pharmacology最新文献_第2页

Cardiac Immunotherapy, Immuno-Cardiology, and the Future of Cardiovascular Pharmacology. 心脏免疫治疗、免疫心脏病学和心血管药理学的未来。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001687

Giuseppe Biondi-Zoccai, Brittany N Weber, Antonio Abbate, George W Booz

{"title":"Cardiac Immunotherapy, Immuno-Cardiology, and the Future of Cardiovascular Pharmacology.","authors":"Giuseppe Biondi-Zoccai, Brittany N Weber, Antonio Abbate, George W Booz","doi":"10.1097/FJC.0000000000001687","DOIUrl":"10.1097/FJC.0000000000001687","url":null,"abstract":"Abstract: Immuno-cardiology is an emerging field that explores the interplay between the immune system, inflammation, and cardiovascular health/disease, aiming to develop innovative therapies for preventing and treating cardiac diseases. Indeed, chronic inflammation and immune dysregulation play pivotal roles in most cardiovascular conditions, including arrhythmias, atherothrombosis, ischemic heart disease, heart failure, and valve disease. Recent advances in immune-based therapies, including chimeric antigen receptor-T and chimeric antigen receptor-macrophage technologies, have demonstrated potential in impacting on cardiac fibrosis and thus improving surrogate end points in preclinical studies. Immune checkpoint inhibitors, while already established as an effective intervention in oncology, present challenges in their cardiovascular applications because of cardiotoxic side effects, highlighting the need for dedicated cardioprotective strategies or further molecular refinements. Nanoparticle-based delivery systems and cytokine-targeted therapies may offer precise modulation of immune responses, while gut microbiota interventions could exploit the systemic impact of inflammation on cardiovascular health. Despite these quite promising advances, barriers such as safety, scalability, and patient-specific responses must be addressed, and thus precision and personalized approaches will be crucial to overcoming these challenges and ensuring safe and also equitable access. By leveraging interdisciplinary collaboration and technological innovations, immuno-cardiology holds the promise of transforming the prevention and treatment landscape for cardiac diseases, paving the way for improved outcomes and quality of life for patients worldwide.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"308-311"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decastatin, a Novel Non-Collagenous 1 Domain From Collagen Type X, Harbors a Specific Fragment With Antiangiogenic Properties. Decastatin是一种来自X型胶原蛋白的新型非胶原1结构域，含有具有抗血管生成特性的特定片段。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001683

Stine Marie Jansen, Rastislav Pitek, Morten Asser Karsdal, Kim Henriksen

{"title":"Decastatin, a Novel Non-Collagenous 1 Domain From Collagen Type X, Harbors a Specific Fragment With Antiangiogenic Properties.","authors":"Stine Marie Jansen, Rastislav Pitek, Morten Asser Karsdal, Kim Henriksen","doi":"10.1097/FJC.0000000000001683","DOIUrl":"10.1097/FJC.0000000000001683","url":null,"abstract":"Abstract: The NC1 domains of collagens have been shown to possess antiangiogenic potential and, therefore, are of therapeutic interest for cancer. However, endostatin and other NC1 domains have not been successful in clinical tests. Therefore, we used evolutionary conservation to perform molecular deconstruction of the domains to further understand their structure-activity relationship, thereby deciphering their antiangiogenic potential. Homology exploration revealed that collagen type X contains a highly interesting NC1 domain (decastatin), with several sequences showing significant homology with vastatin, which is a known collagen type VIII-derived NC1 domain. For comparison, endostatin and vastatin were split into fragments, some of which contained highly conserved regions. The testing of these peptides revealed that the peptides containing conserved regions induced signaling, and fragment 4 of decastatin showed the highest potency of all fragments, with a calculated inhibitory concentration value of 2.7 μM in the human umbilical vein endothelial cell-based tube formation assay, which is like that of an intact NC1 domain. Notably, the corresponding fragment from vastatin (V4) also inhibited tube formation, suggesting that this region is of therapeutic interest. In summary, we used evolutionary conservation to identify a novel NC1 domain of collagen type X, a collagen playing a role in angiogenesis of the growth plate. Furthermore, we provided data indicating that the antiangiogenic activity of NC1 domain-derived peptides reside within their conserved domains. As a result, we identified a fragment called Decastatin fragment 4 (D4) derived from the NC1 domain of collagen type X, and which has potent antiangiogenic activity.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"369-380"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Game Changer for Resistant Hypertension: The Rise of Aprocitentan. 顽固性高血压的游戏规则改变者：阿普昔坦的兴起。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001679

Ali H Eid

{"title":"A Game Changer for Resistant Hypertension: The Rise of Aprocitentan.","authors":"Ali H Eid","doi":"10.1097/FJC.0000000000001679","DOIUrl":"10.1097/FJC.0000000000001679","url":null,"abstract":"Abstract: Hypertension is a major risk factor for cardiovascular disease, and a major contributor to global morbidity and mortality. In particular, resistant hypertension (rHTN), defined as blood pressure that remains elevated despite treatment with at least three antihypertensive agents including a diuretic, continues to be a major pharmacotherapeutic challenge. Traditional antihypertensive drugs often fail in patients with rHTN, underscoring the need for novel therapies. This is a brief mini-review of aprocitentan, a new drug that promises a glimmer of hope for patients with rHTN. This drug is a dual endothelin (ET) receptor antagonist that blocks both ET A and ET B receptors. Given that these two receptors are critical players in vasotone regulation, antagonizing them, such as by aprocitentan, would be expected to significantly reduce blood pressure in patients with rHTN. Indeed, the PRECISION clinical trial demonstrated aprocitentan's superior effectiveness in reducing blood pressure in resistant patients, and the effects were sustained. Aprocitentan has been recently FDA-approved, marking a major milestone in hypertension management, offering hope for patients with difficult-to-treat hypertension.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"312-315"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGLT2 Inhibitors in the Elderly: Redefining Cardiac Care Beyond Age. SGLT2抑制剂在老年人中的应用：重新定义年龄以外的心脏护理。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001680

Marco Giuseppe Del Buono, Simone Filomia, Gianluigi Saponara, Tommaso Sanna

引用次数: 0

Pantothenate Kinase 1 Identified as a Direct Target of SGLT2 Inhibitors in the Heart. 泛酸激酶1 （PANK1）被确定为心脏中SGLT2抑制剂的直接靶点。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001689

Ghadir Amin, George W Booz, Fouad A Zouein

引用次数: 0

Comparing the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors Among Nonolder and Older Patients: A Systematic Review and Meta-Analysis. 比较钠-葡萄糖共转运蛋白2抑制剂在非老年和老年患者中的疗效：一项系统回顾和荟萃分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001659

Izuki Yamashita, Tomohiro Fujisaki, Francisco J Romeo, Daisuke Sueta, Eiichiro Yamamoto, Kenichi Tsujita

{"title":"Comparing the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors Among Nonolder and Older Patients: A Systematic Review and Meta-Analysis.","authors":"Izuki Yamashita, Tomohiro Fujisaki, Francisco J Romeo, Daisuke Sueta, Eiichiro Yamamoto, Kenichi Tsujita","doi":"10.1097/FJC.0000000000001659","DOIUrl":"10.1097/FJC.0000000000001659","url":null,"abstract":"Abstract: Large scale randomized trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors can reduce cardiovascular events in patients with cardiovascular disease or with increased risks of cardiovascular disease. However, the evidence from older patients is limited. To compare the efficacy of SGLT2 inhibitors among nonolder and older patients, we have searched PubMed, Cochrane Central, and Embase until February 2023 for randomized controlled trials investigating SGLT2 inhibitors in older (age ≥65 years) patients with diabetes mellitus, chronic kidney disease, and chronic heart failure. The primary outcome was a composite outcome of cardiovascular death, acute myocardial infarction, and stroke. The secondary outcomes were exacerbation of heart failure, kidney disease progression, and a composite of cardiovascular death and heart failure. Our search identified 11 randomized controlled trials with a total of 79,370 patients. SGLT2 inhibitors were associated with a reduced risk of the primary outcome in the total cohort [hazard ratio (HR): 0.91; confidence intervals (CI), 0.84-0.99] with concordant results in both nonolder and older populations (HR: 0.96; CI, 0.88-1.05, HR: 0.87; CI, 0.75-1.01, respectively) without subgroup differences ( P = 0.23), and a reduced risk of developing the composite of cardiovascular death and heart failure exacerbation in both nonolder and older populations (HR: 0.77; CI, 0.67-0.87, HR: 0.76; CI, 0.71-0.82, respectively) without subgroup differences ( P = 0.96). A meta-analysis could not be performed for the other outcomes. These results suggested that SGLT2 inhibitors were similarly associated with reduced risks of cardiovascular events across the spectrum of nonolder and older patients with risk factors for developing cardiovascular disease.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"329-337"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship Between Aldehyde Dehydrogenase 2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries. ALDH2基因多态性与硝酸甘油对冠状动脉血管扩张作用的关系

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001682

Kai Zhang, Chi He, Yaliang Tong, Yuquan He

{"title":"Relationship Between Aldehyde Dehydrogenase 2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.","authors":"Kai Zhang, Chi He, Yaliang Tong, Yuquan He","doi":"10.1097/FJC.0000000000001682","DOIUrl":"10.1097/FJC.0000000000001682","url":null,"abstract":"Abstract: Aldehyde dehydrogenase 2 (ALDH2) is a key enzyme that facilitates the biologic metabolism of nitroglycerin. However, no study investigated the association between ALDH2 gene polymorphism and the vasodilation of coronary arteries after intracoronary administration of nitroglycerin. In this study, we enrolled 427 patients with suspected angina pectoris. ALDH2 genotyping was performed and all patients were given 200 µg nitroglycerin in the right coronary artery during the coronary angiography. The invasive hemodynamic parameters including systolic blood pressure (SBP), diastolic blood pressure, and heart rate were monitored. The reference diameter and stenosis diameter of the right coronary artery were measured with the Stenosis Analysis 1.6 software. Both wild-type and mutant-type groups exhibited significant decreases in SBP, diastolic blood pressure values, and increases in heart rate value after administration of nitroglycerin ( P < 0.05). The wild-type group showed significantly higher absolute difference values in SBP than the mutant-type group ( P < 0.05). The mutant-type group exhibited significantly lower difference values and rates of change in reference diameter than the wild-type group [0.3 ± 0.3 vs. 0.5 ± 0.2, P < 0.001 for the difference value of diameter; 9.6 ± 9.5 vs. 15.8 ± 8.5, P < 0.001 for the rate of change (%)]. Conversely, no differences were observed between the wild-type and mutant-type groups in terms of the difference value and rate of change of the stenosis diameter ( P > 0.05). In conclusion, ALDH2 gene polymorphism (Glu504Lys) is associated with changes in invasive hemodynamic parameters and coronary artery diameter after intracoronary injection of nitroglycerin.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"358-363"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Procyanidin B2 Attenuates Pathologic Cardiac Fibrosis and Inflammation: Role of PPARγ. 原花青素B2减轻病理性心肌纤维化和炎症：PPARγ的作用。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001684

Chun Xia Li, Ruo Man Wu, Qian Lin Xie, Fei Wang, Xiao Le Xu

{"title":"Procyanidin B2 Attenuates Pathologic Cardiac Fibrosis and Inflammation: Role of PPARγ.","authors":"Chun Xia Li, Ruo Man Wu, Qian Lin Xie, Fei Wang, Xiao Le Xu","doi":"10.1097/FJC.0000000000001684","DOIUrl":"10.1097/FJC.0000000000001684","url":null,"abstract":"Abstract: Procyanidin B2 (PB2) is a prominent procyanidin isomer. Its effects and mechanisms in cardiac remodeling are not fully understood. Peroxisome proliferator-activated receptor gamma (PPAR-γ) plays a crucial role in regulating cardiac hypertrophy, fibrosis, and inflammation. This study aims to investigate the effect of PB2 on pathologic cardiac fibrosis and inflammation, focusing on the underlying mechanisms involving PPAR-γ. In vitro, cardiac fibrosis was induced in cardiac fibroblasts using angiotensin II. In vivo, a mouse model of pathologic cardiac fibrosis was generated through transverse aortic constriction to induce pressure overload. We found that PB2 inhibited proliferation, differentiation, collagen accumulation, and the NF-κB inflammation pathway in cardiac fibroblasts triggered by angiotensin II. These inhibitory effects were negated by the PPAR-γ antagonist GW9662 and RNA interference. In addition, PB2 directly elevated PPAR-γ expression in cardiac fibroblasts. Similarly, PB2 alleviated transverse aortic constriction-induced cardiac dysfunction, myocardial fibrosis, and inflammation in mice. These cardioprotective effects of PB2 in vivo were counteracted by coadministration with GW9662. Correspondingly, the upregulation of PPAR-γ protein expression by PB2 in pressure-overloaded hearts was also counteracted by GW9662 coadministration. In conclusion, this study demonstrates that PB2 exerts protective effects against pathologic cardiac fibrosis and inflammation through a PPAR-γ-dependent mechanism.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"338-349"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coupling Interval Ratio to Predict the Beta-Blocker Response Against Premature Ventricular Complexes. 偶联间隔比预测β受体阻滞剂对早衰心室复合体的反应。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-01 DOI: 10.1097/FJC.0000000000001686

Hasan Atmaca, Ertan Yetkin

{"title":"Coupling Interval Ratio to Predict the Beta-Blocker Response Against Premature Ventricular Complexes.","authors":"Hasan Atmaca, Ertan Yetkin","doi":"10.1097/FJC.0000000000001686","DOIUrl":"10.1097/FJC.0000000000001686","url":null,"abstract":"Abstract: Despite the wide-spread use of beta-blockers, unpredictable response and overall low efficacy are the major pitfalls of beta-blocker use for premature ventricular complexes (PVCs). Accordingly, we aimed to reveal Holter-guided electrocardiographic criteria to predict the beta-blocker responder ones of PVCs. A total of 89 patients who had pre- and post-treatment Holter electrocardiogram recordings and fulfilled the inclusion criteria were retrospectively included in the study. Holter recordings were screened for heart rate variability, number of PVCs, heart rate, pre- and postcoupling intervals (CIs) in 3 different time intervals (24:00-08:00 am , 08:00 am -16:00 pm and 16:00 pm -24:00). Forty-three patients were defined as beta-blocker responder group with respect to 70% decrease in PVCs burden. Heart rate variability analysis revealed that there were not statistically significant differences between beta-blocker responder and nonresponder groups. CI ratio [(post-PVC CI + pre-PVC CI)/pre-PVC CI] of responder and nonresponder groups in 24.00 to 8.00 am time interval was statistically different (3.19 vs. 2.91, P = 0.006, respectively). Logistic regression analysis revealed that CI ratios of the PVCs during the 24:00-08:00 am intervals have significantly associated with the beta-blocker responsiveness for PVCs (odds ratio, 9.54; 95% confidence interval, 1.89-48.7; P value: 0.006). Nighttime increased CI ratio, that is, shorter CI time has been found to be an independent predictor of beta-blocker response against PVCs. Therefore, beta-blockers may be preferably recommended for PVCs, especially in those with shorter CI or increased CI ratio.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"364-368"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gene- and cell-based therapy in cardiovascular diseases. 心血管疾病的基因和细胞治疗。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-30 DOI: 10.1097/FJC.0000000000001707

Cuijuan Zhang, Zhihang Du, Rui Chen, Xiaojing Liu, Dan Li

引用次数: 0